Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | KHK | P50053 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480967 | 0.90 | CCR4 (0.43) | HSP90AA1HSP90AB1ROCK2ROCK1ACHE | |
| SCHEMBL3480883 | 0.87 | CCR4 (0.49) | HSP90AA1HSP90AB1ROCK2ROCK1KHK | |
| SCHEMBL8141002 | 0.86 | PSEN1 (0.41) | HSP90AA1HSP90AB1ROCK2ROCK1 | |
| SCHEMBL3480857 | 0.85 | IGLV6-57 (0.38) | HSP90AA1HSP90AB1ROCK2 | |
| SCHEMBL3029387 | 0.83 | ROCK2 (0.50) | HSP90AA1HSP90AB1ROCK2ROCK1ACHE | |
| SCHEMBL8141252 | 0.82 | CCNE1 (0.47) | — | |
| SCHEMBL3480694 | 0.81 | PSEN1 (0.42) | HSP90AA1HSP90AB1ROCK2ROCK1 | |
| SCHEMBL3017764 | 0.81 | ALK (0.46) | HSP90AA1HSP90AB1 | |
| SCHEMBL3480665 | 0.80 | CDK2 (0.41) | — | |
| SCHEMBL3480972 | 0.80 | CDK2 (0.41) | HSP90AA1HSP90AB1ROCK2ROCK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| WO-2008099210-A2 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | PSEN1, PSEN2, APP | HSP90AA1 236/4885HSP90AB1 71/4885ROCK2 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.